Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms—China,December 2022–February 2023  

作　　者：Di Fu Guanhao He Huanlong Li Haomin Tan Xiaohui Ji Ziqiang Lin Jianxiong Hu Tao Liu Jianpeng Xiao Xiaofeng Liang Wenjun Ma 

机构地区：[1]Department of Public Health and Preventive Medicine,School of Medicine,Jinan University,Guangzhou City,Guangdong Province,China [2]Disease Control and Prevention Institute,Jinan University,Guangzhou City,Guangdong Province,China [3]Key Laboratory of Ministry of Education for Viral Pathogenesis&Infection Prevention and Control,Jinan University,Guangzhou City,Guangdong Province,China [4]Fuyang District Center for Disease Control and Prevention,Hangzhou City,Zhejiang Province [5]Guangdong Provincial Institute of Public Health,Guangdong Provincial Center for Disease Control and Prevention,Guangzhou City,Guangdong Province,China

出　　处：《China CDC weekly》2023年第17期369-373,I0001-I0005,共10页中国疾病预防控制中心周报（英文）

基　　金：This study was supported by the National Key Research and Development Program of China(2021YFC2301604);the Young Elite Scientists Sponsorship Program by CAST(2022QNRC001);Emergency Grants for Prevention and Control of SARS-CoV-2 in Guangdong Province(2022A1111090004);the Science and Technology Program of Guangzhou(202102021285).

摘　　要：Summary What is already known about this topic?A considerable percentage of the population has received both primary and booster vaccinations,which could potentially provide protection against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron infections and related symptoms.What is added by this report?The self-reported infection rate,as determined from an online survey,reached its peak(15.5%)between December 19 and 21,2022,with an estimated 82.4%of individuals in China being infected as of February 7,2023.During the epidemic,the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0%within three months of vaccination and 37.9%between 3 and 6 months following vaccination.Furthermore,the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7%to 83.2%within three months and from 25.9%to 69.0%between 3 and 6 months post-booster vaccination.

关 键 词：VACCINATION prevention acute 

分 类 号：R563.1[医药卫生—呼吸系统]